Latest Financial Position News

Skylark Minerals has reshaped its leadership team with seasoned gold industry veterans and agreed to divest its Citronen Zn-Pb Project, positioning the company for renewed growth and exploration success.

Hammer Metals Limited reports steady progress in its December 2024 quarter with multiple drilling programs underway across its Mount Isa copper-gold projects, while assay results from recent campaigns are eagerly awaited.

Global Lithium Resources pauses Definitive Feasibility Study on its flagship Manna Lithium Project due to challenging lithium markets, while advancing strategic acquisitions and exploration in Western Australia.

Alpha HPA Limited has reached a major funding milestone with a $400 million senior debt package for its HPA First Project Stage 2, while experiencing accelerating demand from the semiconductor sector and advancing new product developments.

Neurotech International reports key clinical progress in paediatric neurological disorders, securing FDA orphan drug designation for its Rett Syndrome treatment and advancing pivotal trials for ASD and PANDAS/PANS.

Lykos Metals Limited narrows its Sockovac project tenement while securing an extended exploration permit for Jezero, positioning itself for focused growth in Bosnia and Herzegovina.

Victory Metals advances its North Stanmore Heavy Rare Earth Project with a strategic offtake MOU signed with Sumitomo Corporation and a significant upgrade to its mineral resource estimate, reinforcing its position in the critical rare earths sector.

Rox Resources has completed its $27 million capital raising with the final tranche of shares issued to institutional investors and company directors, signaling strong backing for its growth plans.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Jervois Global Limited has initiated a prepackaged Chapter 11 recapitalisation process in the US, leading to the suspension of its shares on multiple exchanges. Shareholders are being notified with detailed documentation as the company seeks to restructure its finances.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

Infinity Lithium reports steady progress on its San José Lithium Project with updated mining licence requirements and a strategic pivot to new European funding opportunities.